Analyst Upgrades – Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Gets Upgraded By Oppenheimer Holdings, Inc. from Market Perform to Outperform

ME Staff
-
0

Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)

Today, Alexion Pharmaceuticals (NASDAQ:ALXN) stock received an upgrade by Oppenheimer Holdings, Inc. from Market Perform to Outperform with a price target of $175.00.

There are 5 hold ratings, 17 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy (Score: 2.83) with a consensus target price of $159.32 per share, a potential 18.97% upside.

Some recent analyst ratings include

  • 7/28/2017-Oppenheimer Holdings, Inc. Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 7/28/2017-Morgan Stanley Reiterated Rating of Overweight.
  • 7/14/2017-SunTrust Banks, Inc. Reiterated Rating of Buy.
  • 7/3/2017-Cowen and Company Reiterated Rating of Outperform.
  • 6/26/2017-Robert W. Baird Reiterated Rating of Neutral.
  • 6/22/2017-Leerink Swann Reiterated Rating of Outperform.

Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 94.84%.

  • On 6/15/2017 Bros. Advisors Lp Baker, Director, bought 660,779 with an average share price of $117.33 per share and the total transaction amounting to $77,529,200.07. View SEC Filing
  • On 6/14/2017 Bros. Advisors Lp Baker, Director, bought 1,348,955 with an average share price of $116.32 per share and the total transaction amounting to $156,910,445.60. View SEC Filing
  • On 6/14/2017 Ludwig Hantson, CEO, bought 10,000 with an average share price of $116.72 per share and the total transaction amounting to $1,167,200.00. View SEC Filing
  • On 3/1/2017 Clare Carmichael, EVP, sold 2,179 with an average share price of $131.66 per share and the total transaction amounting to $286,887.14. View SEC Filing
  • On 3/1/2017 Heidi L Wagner, SVP, sold 994 with an average share price of $131.65 per share and the total transaction amounting to $130,860.10. View SEC Filing
  • On 3/1/2017 Leonard Bell, Director, sold 3,978 with an average share price of $131.96 per share and the total transaction amounting to $524,936.88. View SEC Filing
  • On 2/28/2017 Carsten Thiel, EVP, sold 125 with an average share price of $74.52 per share and the total transaction amounting to $9,315.00. View SEC Filing

Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 133.92 0.00 0.00% with 5,175,499 shares trading hands.